Retatrutide
What does "Triple Hormone Receptor Agonist" mean?
This is the newest class of incretin-based peptides. While some peptides activate one receptor and others activate two, retatrutide activates THREE receptors: GIP, GLP-1, and glucagon receptors.
Explained Simply
If semaglutide pushes one "full" button and tirzepatide pushes two, retatrutide pushes THREE buttons at once. The extra button (glucagon receptor) is like a metabolism boost button.
How It Works
Retatrutide activates three different hormone receptors. GLP-1 receptor activation suppresses appetite and improves insulin release. GIP receptor activation enhances insulin secretion. Glucagon receptor activation may increase energy expenditure.
Research by Sex
Effects in Men
- •Phase 2 trials show significant metabolic improvements in male participants
- •Research indicates robust response in body composition changes
- •Visceral fat reduction appears pronounced in male subjects
Effects in Women
- •Clinical trial data shows strong efficacy in female participants
- •Weight reduction outcomes comparable to male participants
- •Metabolic improvements observed across hormonal phases
Key Terms Explained
Triple agonist
A compound that activates three different receptor types
Glucagon
A hormone that raises blood sugar and increases energy expenditure
Thermogenesis
The production of heat in the body, which burns calories
Research Areas
- •Triple receptor agonism mechanisms
- •Comparative studies with dual agonists
- •Energy expenditure and thermogenesis
- •Dose-response relationships
Published Studies
Laboratory Protocols
Storage
Store lyophilized peptide at -20°C.
Reconstitution
Reconstitute with provided diluent or bacteriostatic water.
Quick Facts
Category
Triple Hormone Receptor Agonist
Molecular Weight
~5000 g/mol
Half-Life
~6 days
Amino Acid Sequence
Modified GLP-1/GIP/Glucagon triple agonist
Grokipedia
Quick Reference
View detailed research data including key facts, mechanism of action, and safety profile.
Disclaimer: This information is provided for educational purposes only. These products are intended for laboratory research use only. Not for human consumption.
Grokipedia
Quick Reference
Retatrutide
Retatrutide is an investigational triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. It represents the newest class of incretin-based therapies with enhanced efficacy potential.
Key Facts
- •Triple receptor agonist (GIP/GLP-1/Glucagon)
- •Half-life: approximately 6 days
- •Phase 2 trials show significant efficacy
- •Balanced agonism across all three receptors
- •Once-weekly dosing in clinical studies
Mechanism of Action
Activates three hormone receptors: GLP-1 suppresses appetite and improves insulin release; GIP enhances insulin secretion; Glucagon increases energy expenditure and thermogenesis. The triple activation may provide superior metabolic benefits.
Research Applications
- Metabolic research and weight management
- Glucose metabolism studies
- Energy expenditure research
- Body composition optimization
Safety Profile
Investigational compound. Phase 2 trials ongoing. Common GLP-1 class effects may include GI symptoms. Research use only.
Disclaimer: This information is for educational and research purposes only. Products are intended for laboratory research use only. Not for human consumption.